Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Long-Term Investments (2020 - 2021)

Tango Therapeutics (TNGX) has 2 years of Long-Term Investments data on record, last reported at $166.8 million in Q2 2021.

  • For Q2 2021, Long-Term Investments changed N/A year-over-year to $166.8 million; the TTM value through Jun 2021 reached $166.8 million, changed N/A, while the annual FY2020 figure was $166.8 million, N/A changed from the prior year.
  • Long-Term Investments reached $166.8 million in Q2 2021 per TNGX's latest filing, roughly flat from $166.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $166.8 million in Q4 2020 and bottomed at $166.8 million in Q3 2020.